-- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing






Exhibit 10.3(b)


BioCurex


AMENDMENT TO SEMI-EXCLUSIVE LICENSE AGREEMENT


     THIS AMENDMENT TO SEMI-EXCLUSIVE LICENSE AGREEMENT
(hereinafter, “Agreement”),
effective as of June 1st, 2007 (hereinafter, the “Amendment
Date”), is made by and between Abbott Laboratories, a corporation of
the State of Illinois, having its principal place of business at 100 Abbott Park
Road, Abbott Park, IL 60064-3500 (hereinafter, “Abbott”) and
BioCurex Inc., a corporation of the State of Texas, having its principal place
of business at 215-7080 River Road, Richmond, BC, Canada, V6X 1X5 (hereinafter, “BioCurex”). 


     WHEREAS, the parties hereto entered into a Semi-Exclusive
  License Agreement (the “Agreement”),
  effective as of April 1, 2005, and desire to amend the Agreement as set forth
herein;


      NOW, THEREFORE, in consideration of the mutual promises, covenants and conditions set forth herein, and for other valuable consideration, the receipt and adequacy of which is hereby acknowledged, Abbott and BioCurex hereby amend
the Agreement as follows: 

	
      1.      		
The words “Subject to Section 2.6 below” shall
    be added in Section 2.1 after
    the heading “License.”
	
	 
	
      2.      		
The words “Subject to Section 2.6 below” shall
    be added in Section 2.2 after
    the heading “Exclusive Sublicense Right.”
	
	 
	
      3.      		
The following shall be added to the end of Section 2.5:
	
	 
	 	
The parties hereto recognize the BioCurex has performed certain Research and Development that would have been performed by Abbott under this Section 2.5, and that BioCurex has been reimbursed for the same under
Section 4.2 on the Amendment Date. That Abbott has not performed certain Research and Development under this Section 2.5 prior to the Amendment Date shall not be deemed to be an event of default by Abbott under this Agreement.

	
	 
	
      4.      		
A new Section 2.7 shall be added, as follows:
	
	 
	 	
  2.7      		
Retention of Rights. Notwithstanding anything to the contrary in this Agreement, BioCurex retains the right to:
	
	 
	 	 	
  (a)      		
develop, produce, license, market, sell and distribute (directly or through third parties acting on its behalf) non-automated RECAF microplate assays to third parties with the restriction that they may not automate
or use in conjunction with instrumentation, e.g., automated pippeting apparatus; and
	
	 









	 	 	(b)      	retain all revenues received
          in connection with such activities with no royalties or other payments
          to be made to Abbott by reason thereof;

	 	 	 	 
	 	 	 	and the same shall not be subject
        to any restrictions, including but not limited to any semi-exclusivity
    provisions and limitations, set forth in this Agreement. 
	 	 	 	 
	5.	Except as amended hereby, the
        Agreement is hereby ratified and affirmed and remains in full force and
    effect as of the date hereof. 



     IN WITNESS WHEREOF, each party hereto has caused this Amendment to Semi-Exclusive License Agreement to be executed by its duly authorized representatives as of the Amendment Date. 

	
    Abbott Laboratories		 	  	
      BioCurex Inc.		 
	  
	  
	By:	/s/
      JOSEPH M. NEMMERS, JR. 	 	  	By:	/s/
    RICARDO MORO	 
	Name:	
 Joseph M. Nemmers, Jr.		 	  	Name:	
 Dr. Ricardo Moro		 
	Title:	
 Sr. Vice President,		 	  	Title:	
 President and CEO		 
	 	
       Diagnostic Operations 	 	  	 	  	 
	 	
      President, Diagnostics Division 	 	  	 	  	 







2